首页|基于网络药理学的乌黄骨外散治疗类风湿关节炎配伍合理性研究

基于网络药理学的乌黄骨外散治疗类风湿关节炎配伍合理性研究

扫码查看
目的 探索乌黄骨外散治疗类风湿关节炎的配伍合理性.方法 采用网络药理学方法,分别对乌黄骨外散中祛风湿组(生川乌、生草乌)、解表组(桂枝、细辛、白芷、薄荷)和清热组(大黄、黄柏)作用于类风湿关节炎的靶点、功能和通路进行预测和筛选,通过数据整合分析解析乌黄骨外散治疗类风湿关节炎的作用特点及配伍规律.结果 乌黄骨外散各拆方组共得到 90 个活性成分和 360 个靶点,富集得到 237 个KEGG通路;主要涉及炎症反应、病毒感染、内分泌调控、痛觉控制、血脂调控等相关过程.结论 乌黄骨外散各拆方组在协同治疗类风湿关节炎的基础上,调控作用各有侧重.祛风湿组长于抗炎止痛和调节内分泌,解表组和清热组主要参与感染调控、炎症免疫反应和血脂调控.结果 表明祛风湿组做为君药,在解表组和清热组的辅佐下协同发挥治疗作用,乌黄骨外散配伍合理.
Study on compatibility rationality of Wuhuang Guwai Powder for the treatment of rheumatoid arthritis based on network pharmacology
Objective To explore the compatibility rationality of Wuhuang Guwai Powder for the treatment of rheumatoid arthritis.Methods Network pharmacology was used to predict and screen the targets,function and pathways related to rheumatoid arthritis in Wuhuang Guwai Powder including dispelling wind dampness group(DWDG),relieving exterior syndrome group(RESG),heat-clearing and detoxicating group(HCDG).The characteristics and compatibility rules of this prescription in treating RA were analyzed combined with data.Results A total of 90 active components and 360 targets were obtained,and 237 KEGG pathways were enriched in herb groups of Wuhuang Guwai Powder;It mainly involves inflammatory reaction,virus infection,endocrine regulation,pain control,blood lipid regulation and other related processes.Conclusion On the basis of the synergistic treatment of rheumatoid arthritis,herb groups of Wuhuang Guwai Powder has its own function characteristics.DWDG were mainly related to anti inflammation,pain relief and endocrine regulation.RESG and HCDG was mainly involved in infection regulation,inflammatory immune response and lipid regulation.The results showed that DWDG as the king drugs,played a synergistic therapeutic role with the help of the RESG and HCDG,and the compatibility of Wuhuang Guwai Powder was reasonable.

Wuhuang Guwai PowderRheumatoid arthritisNetwork pharmacologyCompatibility rationality

孙毅东、张慧、陈宝婷、张素方、杨婷玉

展开 >

广州中医药大学第二附属医院/广东省中医院珠海医院,广东珠海 519015

乌黄骨外散 类风湿关节炎 网络药理学 配伍合理性

广东省中医药科研项目广东省中医药科研项目

2022220520202173

2023

中国处方药
南方医药经济研究所

中国处方药

影响因子:0.649
ISSN:1671-945X
年,卷(期):2023.21(12)
  • 11